NeoGenomics, Inc. Deferred State and Local Income Tax Expense (Benefit)
NeoGenomics, Inc. (NEO) reported Deferred State and Local Income Tax Expense (Benefit) of $165.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-02-17
- NeoGenomics, Inc. deferred state and local income tax expense (benefit) for fiscal 2025 was $165.00K, a 1733.33% increase from fiscal 2024.
- NeoGenomics, Inc. deferred state and local income tax expense (benefit) for fiscal 2024 was $9.00K, a 98.50% decline from fiscal 2023.
- NeoGenomics, Inc. deferred state and local income tax expense (benefit) for fiscal 2023 was $602.00K.
- NeoGenomics, Inc. deferred state and local income tax expense (benefit) for fiscal 2022 was -$647.00K, a 152.14% decline from fiscal 2021.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $165.00K 10-K · filed 2026-02-17 |
| 2024-12-31 | $9.00K 10-K · filed 2026-02-17 |
| 2023-12-31 | $602.00K 10-K · filed 2026-02-17 |
| 2022-12-31 | -$647.00K 10-K · filed 2025-02-18 |
| 2021-12-31 | $1.24M 10-K · filed 2024-02-20 |
| 2020-12-31 | -$5.21M 10-K · filed 2023-02-24 |
| 2019-12-31 | -$939.00K 10-K · filed 2022-02-25 |
| 2018-12-31 | $321.00K 10-K · filed 2021-02-25 |
| 2017-12-31 | $297.00K 10-K · filed 2020-02-28 |
| 2016-12-31 | -$281.00K 10-K · filed 2019-02-26 |
| 2015-12-31 | -$245.00K 10-K · filed 2018-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |